The **U.S. Food and Drug Administration (FDA)** has officially accepted a **New Drug Application (NDA)** for **encaleret**, a novel therapeutic candidate developed by **BridgeBio Pharma**. This regulatory milestone marks a significant step forward for patients diagnosed with **Autosomal Dominant Hypocalcemia Type 1 (ADH1)**, a rare genetic disorder characterized by persistent low levels of calcium in the blood and high levels of urinary calcium excretion.
**ADH1** is triggered by gain-of-function variants in the **calcium-sensing receptor (CaSR)** gene. These mutations cause the receptors to become hypersensitive to extracellular calcium, leading the body to inaccurately perceive calcium levels as being higher than they actually are. Consequently, patients suffer from chronic hypocalcemia, which can cause neuromuscular irritability, seizures, and long-term renal complications.
The **NDA** submission is primarily supported by data from the **Phase 3 CALHEART study**. This clinical trial evaluated the safety and efficacy of **encaleret**, a small-molecule **CaSR antagonist**. By selectively inhibiting the overactive receptors, the drug aims to normalize both blood calcium concentrations and urinary calcium excretion, thereby addressing the root physiological imbalance of the condition.
The investigative team reported that participants treated with **encaleret** demonstrated a rapid normalization of serum calcium levels. Furthermore, the therapy showed promise in reducing the risk of nephrocalcinosis and other renal impairments often associated with standard-of-care treatments, such as vitamin D analogs and calcium supplementation. Traditional therapies often fail to achieve optimal physiological balance and can inadvertently exacerbate hypercalciuria, increasing the risk of kidney stones and chronic kidney disease.
The **FDA** has granted a **Priority Review** designation for this application, signaling the urgent unmet medical need within the **ADH1** patient community. With this acceptance, the agency has set a **Prescription Drug User Fee Act (PDUFA)** target action date for the first half of 2025. If approved, **encaleret** would represent the first precision medicine specifically indicated for the treatment of this rare genetic electrolyte disorder.
Clinical experts remain optimistic that this therapy will shift the current treatment paradigm. By moving away from general supplementation toward a targeted molecular intervention, healthcare providers may soon be able to offer a more effective strategy for maintaining bone health and systemic mineral homeostasis in patients living with this lifelong condition. As the regulatory review process continues, the medical community awaits final data on long-term safety profiles and broader clinical implementation strategies.
